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Estrogens, such as estrone, estradiol and estriol, were tested as possible antioxidants of lipid peroxidation 
induced by Fe3+-ADP-adriamycin or Fe 3+-ADP-ascorbate. The estrogens with phenolic structure possessed 
substantial activities with respect o the inhibition of lipid peroxidation. Concentrations of estradiol and 
estriol required to achieve 50% inhibition of membrane phospholipid peroxidation were about 4- and 6-times 
that of a-tocopherol, respectively 
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1. INTRODUCTION 
It has been reported that thyroxine with a 
phenolic structure possesses a potent antioxidant 
activity on iron-induced phospholipid peroxida- 
tion [l]. In contrast to all other natural steroids, 
estrogens, estrone and its analog, have a phenolic 
structure in their molecules (ring A). The present 
work was undertaken to prove possible antioxidant 
activities of estrogens, using the Fe3+-ADP- 
adriamycin complex system or the Fe’+-ADP- 
ascorbate system as an initiator of lipid peroxida- 
tion and microsomal phospholipid liposomes as 
lipid source. 
2. MATERIALS AND METHODS 
2.1. Preparation of liposomes 
Microsomal phospholipid was obtained from rat 
liver microsomes as described [2]. Liposomes were 
then prepared by mixing the phospholipid with or 
without the compound (estrone, estradiol, estriol, 
Correspondence address: M. Nakano, College of 
Medical Care and Technology, Gunma University, 
Maebashi, Gunma, Japan 
testosterone or DL+tocopherol) in chloroform- 
methanol (2: 1, v/v), evaporating the organic 
solvents to dryness and sonicating the residue 
suspended in 0.1 M Tris-HCl buffer at pH 7.5 [2]. 
Estrone, estradiol, estriol and testosterone were 
purchased from Sigma. DL-cu-Tocopherol was 
kindly by Eisai Co. 
2.2. Incubation experiments 
The incubation mixture contained liposomes 
(0.85 pmol of lipid phosphorus/ml) with or 
without fatty soluble compound at a variety of 
concentrations, 0.1 mM Fe3+-1.67 mM ADP- 
0.2 mM adriamycin and 0.1 M Tris-HCl buffer at 
pH 7.5 in a total volume of 3.8 ml (for 02 con- 
sumption) and 6.0 ml (for lipid analysis). The reac- 
tion was initiated by the addition of adriamycin. In 
some cases, the mixture contained 0.1 mM 
Fe3+-1 .67 mM ADP-0.5 mM ascorbate, instead of 
the Fe3+-ADP-adriamycin complex (WAC) in the 
above mixture. The reaction was initiated by the 
addition of ascorbate. All incubation experiments 
were carried out at 37°C. 
2.3. Assay 
The lipid peroxidation was monitored mainly by 
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oxygen consumption [2] and in some cases by the 
change in fatty acid composition [2]. The values 
obtained were compared with and corrected for 
those from adequate controls. 
3. RESULTS 
IAAC in Tris-HCl buffer, which is known to be 
converted to Fe2+-ADP-adriamycin by self reduc- 
tion during the incubation [2,3], consumed 02, but 
to a lesser extent. The exposure of unsaturated 
phospholipid liposomes to IAAC caused a strong 
02 consumption, which increased linearly with in- 
creasing time after a short lag time. Estrone or 
estriol in the liposomes inhibited the 02 consump- 
tion seen in the IAAC induced lipid peroxidation 
system. Testosterone, which has no phenolic struc- 
ture in the molecule, had no inhibitory effect. 
However, the mode of inhibition produced by 
estrone or estriol is strikingly different from that 
displayed by a reference compound cu-tocopherol 
in that the latter has a long lag time before 
reaching the maximal rate of 02 consumption. 
These results are shown in fig.1. 
To prove the ability of each steroid or cy- 
tocopherol to inhibit the IAAC-induced lipid 
peroxidation, each compound at a variety of con- 
centrations was incorporated into unsaturated 
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Fig.1. Oxygen consumption in IAAC (Fe’+-ADP- 
adriamycin complex) system, CS (complete system 
containing liposomes and IAAC), or CS with the 
compounds l-4. Number in parentheses represents he 
concentration of the compound, pM. Compounds were: 
1, estrone; 2, estriol; 3, testosterone; 4, tocopherol. 
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phospholipid liposomes and exposed to IAAC for 
measuring 02 consumption. An adequate control 
was also taken. Thus the inhibition by the com- 
pound could be expressed, in terms of %, ac- 
cording to the following equation: 
070 of inhibition = ~ A-% 100 
A-B 
where A, B and C are the maximal 02 consumption 
in the liposome-IAAC, IAAC and liposome-in- 
hibitor-IAAC systems, respectively. Fig.2 shows 
the relationship between % of inhibition and con- 
centration of a compound. From the curves in the 
figure, the concentrations of estradiol and estriol 
required to achieve 50% inhibition could be 
calculated to be 4-times and 6-times that of a- 
tocopherol, respectively. Estrone, however, did 
not elevate the degree of inhibition at concentra- 
tions above 25 ,uM, suggesting limited incorpora- 
tion of this steroid into liposomes under our 
experimental conditions. To ensure the inhibition 
of lipid peroxidation by estriol, the liposomes with 
or without this steroid were exposed to IAAC or 
Fe3+-ADP-ascorbate for 30 min, followed by the 
analysis of fatty acids in the liposomes. The results 
obtained are shown in table 1, indicating that a 
peroxidative cleavage of polyunsaturated fatty 
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Fig.2. Relationship between Vo of inhibition and the 
concentration of the compound. Compounds were: 1, 
estrone; 2, estriol; 2’, estradiol; 3, testosterone; 4, 
tocopherol. 
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Table 1 
Fatty acid composition in phospholipids incubated with various components for 30 min 
Incubation system Fatty acid composition (mol/lOo mol palmitic acid) 
16:0 18:0 18:l 18:2 20:4 22:6 
Sl, basal “) 100.0 85.7 37.6 54.2 101.3 30.9 
S2, Sl + Fe3+-ADP-adriamycin 100.0 84.5 37.9 48.4 65.9 16.1 
S3, S2 + 1OOpM estriol 100.0 88.7 40.2 51.3 90.9 26.8 
S4, Sl + Fe3+-ADP-ascorbate 100.0 89.7 39.1 50.5 86.3 24.1 
S5, S4 + 100 pM estriol 100.0 85.4 39.4 54.9 102.1 30.5 
“) Microsomal phospholipid liposomes (5.1 umol lipid phosphorus) in 6 ml of 0.1 M Tris-HCl buf- 
fer (pH 7.5) 
acids is significantly inhibited by estriol at the con- 
centration used. 
4. DISCUSSION 
The concentration of total estrogens in 
peripheral blood is varied by the function of 
hormone-productive organs, but it is as low as 
about 1 pmol/l even at the last stage of pregnancy 
[4]. However, the hormones would be highly con- 
centrated in cells of their target organs and 
hormone-productive organs. Furthermore estrone 
and estradiol in the cell membrane could be mainly 
metabolized to their catechol analogs [5], which 
have strong activities in inhibiting lipid peroxida- 
tion, identical to that of a-tocopherol [6]. In 
uterus, receptors of estrogens are known to be 
abundant in the nucleus [7] in which estrogens 
could be concentrated thereby protecting the 
nuclear membrane from peroxidative cleavage. 
The placenta at the last stage of pregnancy con- 
tains estrogens at 12.5 pmol/kg wet tissue [8], 
which would be enough to protect the cell mem- 
brane from phospholipid peroxidation under mild 
oxidative conditions. 
Even though the mechanism for inhibiting lipid 
peroxidation by female hormones is unknown at 
present, estrogens may donate hydrogen atoms 
from their phenolic hydroxyl groups to lipid 
peroxyradicals for terminating chain reactions. 
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